Top

Current Treatment Options in Gastroenterology

Published in:

01-03-2018 | Esophagus (PG Iyer, Section Editor)

Recent Advances in Screening for Barrett’s Esophagus

Authors: Sarmed S. Sami, MRCP PhD, Prasad G. Iyer, MD MS

Published in: Current Treatment Options in Gastroenterology | Issue 1/2018

Opinion statement

Purpose of review

There is a pressing need for effective strategies to halt the increase in both the incidence and mortality of esophageal adenocarcinoma (EAC). Screening for Barrett’s esophagus, which is the only known precursor of EAC, remains a ripe area for research, particularly with regard to identifying the target population, screening tools, and management of screen-detected populations. This review aims to explore in depth the rationale for screening for Barrett’s esophagus, recent biotechnological advances which may have the potential of making screening feasible, and also highlight the challenges which will have to be overcome in order make screening for BE a realistic prospect.

Recent findings

Imaging techniques such as portable transnasal endoscopy have the advantage of providing an immediate diagnosis of Barrett’s esophagus as well as other significant pathologies such as reflux esophagitis and cancer; however, larger studies in non-enriched community screening populations are required to evaluate their feasibility. The capsule sponge is a cell-sampling device coupled with a biomarker, which has been most extensively evaluated with very promising results as regards feasibility, acceptability, accuracy, and cost-effectiveness. Its effectiveness in increasing the detection of Barrett’s esophagus in primary care is currently being evaluated. Several Barrett’s esophagus risk prediction scores have been developed with variable degrees of accuracy.

Summary

Several minimally and non-invasive screening techniques have been studied including imaging and cell-sampling devices. Barrett’s risk assessment models need to be further validated in independent, relevant screening populations with clear cut-offs for recommending screening to be defined.

Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer epidemiology biomarkers and. Prevention. 2010;19(6):1468–70.

Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, et al. Incipient angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s adenocarcinoma. J Clin Oncol. 2002;20(13):2971–9. https://doi.org/10.1200/JCO.2002.09.011.CrossRefPubMed

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6. https://doi.org/10.1093/jnci/dji024.CrossRefPubMed

Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–23. https://doi.org/10.1053/j.gastro.2009.05.059.CrossRefPubMed

Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association symposium. Gastroenterology. 2015;149(6):1599–606. https://doi.org/10.1053/j.gastro.2015.08.007.CrossRefPubMedPubMedCentral

Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122(1):26–33. https://doi.org/10.1053/gast.2002.30297.CrossRefPubMed

Chak A, Faulx A, Eng C, Grady W, Kinnard M, Ochs-Balcom H, et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer. 2006;107(9):2160–6. https://doi.org/10.1002/cncr.22245.CrossRefPubMed

Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83. https://doi.org/10.1056/NEJMoa1103042.CrossRefPubMed

Jung KW, Talley NJ, Romero Y, Katzka DA, Schleck CD, Zinsmeister AR, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106(8):1447–55. https://doi.org/10.1038/ajg.2011.130.CrossRefPubMedPubMedCentral

10.

Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 2010;341(sep10 1):c4372. https://doi.org/10.1136/bmj.c4372.CrossRefPubMedPubMedCentral

11.

•• Ross-Innes CS, Debiram-Beecham I, O'Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12(1):e1001780. https://doi.org/10.1371/journal.pmed.1001780. Large case control study showing the Cytosponge-TFF3 test to be safe, acceptable, and has accuracy comparable to other screening tests. This test may be a simple and inexpensive approach to screen patients for Barrett's esophagus.CrossRefPubMedPubMedCentral

12.

Peery AF, Hoppo T, Garman KS, Dellon ES, Daugherty N, Bream S, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75(5):945–53. https://doi.org/10.1016/j.gie.2012.01.021.CrossRefPubMedPubMedCentral

13.

Shariff MK, Bird-Lieberman EL, O'Donovan M, Abdullahi Z, Liu X, Blazeby J, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc. 2012;75(5):954–61. https://doi.org/10.1016/j.gie.2012.01.029.CrossRefPubMed

14.

•• Sami SS, Dunagan K, Johnson ML, Schleck C, Shah N, Zinsmeister A, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110(1):148–58. Study showed that community mobile unit screening with disposable transnasal endoscopy has equivalent participation rates and effectiveness to hospital screening.CrossRefPubMed

15.

Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42. https://doi.org/10.1136/gutjnl-2013-305372.CrossRefPubMed

16.

Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91. https://doi.org/10.1053/j.gastro.2011.01.030.CrossRefPubMed

17.

Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087–94. https://doi.org/10.1016/j.gie.2012.08.004.CrossRefPubMed

18.

Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50. https://doi.org/10.1038/ajg.2015.322.CrossRefPubMed

19.

Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2016;44(8):775–84. https://doi.org/10.1111/apt.13783.CrossRefPubMed

20.

Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus—associated esophageal adenocarcinomas. Gastroenterology. 2013;145(2):312–9.e1. https://doi.org/10.1053/j.gastro.2013.05.004.CrossRefPubMedPubMedCentral

21.

Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8(3):235–44. https://doi.org/10.1016/j.cgh.2009.10.010.CrossRefPubMed

22.

Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2016;150(3):599–607.e7;quiz e14–5. https://doi.org/10.1053/j.gastro.2015.11.040.CrossRefPubMed

23.

Cooper GS, Yuan Z, Chak A. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer. 2002;95(1):32–8. https://doi.org/10.1002/cncr.10646.CrossRefPubMed

24.

Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol. 2009;104(6):1356–62. https://doi.org/10.1038/ajg.2009.159.CrossRefPubMed

25.

Das A, Singh V, Fleischer DE, Sharma VK. A Comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103(6):1340–5. https://doi.org/10.1111/j.1572-0241.2008.01889.x.CrossRefPubMed

26.

Wani S, Drahos J, Cook MB, Rastogi A, Bansal A, Yen R, et al. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. Gastrointest Endosc. 2014;79(2):224–32 e1. https://doi.org/10.1016/j.gie.2013.08.002.CrossRefPubMed

27.

Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, Based on a Delphi Process. Gastroenterology. 2012;143(2):336–46. https://doi.org/10.1053/j.gastro.2012.04.032.CrossRefPubMedPubMedCentral

28.

Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136(7):2101–14. https://doi.org/10.1053/j.gastro.2009.02.062.CrossRefPubMedPubMedCentral

29.

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, et al. Cost effectiveness of screening patients with gastroesophageal reflux disease for Barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15(9):1397–404. https://doi.org/10.1016/j.cgh.2017.02.017.CrossRefPubMed

30.

UK National Screening Commitee, Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. http://www.screening.nhs.uk/criteria. 2009.

31.

Falk GW, Chittajallu R, Goldblum JR, Biscotti CV, Geisinger KR, Petras RE, et al. Surveillance of patients with Barrett’s esophagus for dysplasia and cancer with balloon cytology. Gastroenterology. 1997;112(6):1787–97. https://doi.org/10.1053/gast.1997.v112.pm9178668.CrossRefPubMed

32.

Rader AE, Faigel DO, Ditomasso J, Magaret N, Burm M, Fennerty MB. Cytological screening for Barrett’s esophagus using a prototype flexible mesh catheter. Dig Dis Sci. 2001;46(12):2681–6. https://doi.org/10.1023/A:1012771328187.CrossRefPubMed

33.

Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144(1):62–73 e6. https://doi.org/10.1053/j.gastro.2012.09.060.CrossRefPubMed

34.

Iyer P, Johnson ML, Lansing R, Yab TC, Taylor WR, Pophali PA, et al. Discovery, validation and feasibility testing of highly discriminant DNA methylation markers for detection of Barrett’s esophagus using a capsule sponge device. Gastroenterology. 2017;150(4):S66–S7. https://doi.org/10.1016/s0016-5085(16)30344-4. CrossRef

35.

Mallick R, Patnaik SK, Wani S, Bansal A. A systematic review of esophageal MicroRNA markers for diagnosis and monitoring of Barrett’s esophagus. Dig Dis Sci. 2016;61(4):1039–50. https://doi.org/10.1007/s10620-015-3959-3.CrossRefPubMed

36.

Bus P, Kestens C, Ten Kate FJ, Peters W, Drenth JP, Roodhart JM, et al. Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma. J Gastroenterol. 2016;51(6):560–70. https://doi.org/10.1007/s00535-015-1133-5.CrossRefPubMed

37.

Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One. 2013;8(4):e57502. https://doi.org/10.1371/journal.pone.0057502.CrossRefPubMedPubMedCentral

38.

Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie HA, Veselkov KA, Hoare JM, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262(6):981–90. https://doi.org/10.1097/sla.0000000000001101.CrossRefPubMed

39.

Chan DK, Zakko L, Visrodia KH, Leggett CL, Lutzke LS, Clemens MA, et al. Breath testing for Barrett’s esophagus using exhaled volatile organic compound profiling with an electronic nose device. Gastroenterology. 2017;152(1):24–6. https://doi.org/10.1053/j.gastro.2016.11.001.CrossRefPubMed

40.

Eliakim R, Sharma VK, Yassin K, Adler SN, Jacob H, Cave DR, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005;39(7):572–8. https://doi.org/10.1097/01.mcg.0000170764.29202.24.CrossRefPubMed

41.

Sharma P, Wani S, Rastogi A, Bansal A, Higbee A, Mathur S, et al. The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett’s esophagus: a blinded, prospective study. Am J Gastroenterol. 2008;103(3):525–32. https://doi.org/10.1111/j.1572-0241.2007.01233.x.CrossRefPubMed

42.

Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104(6):1533–9. https://doi.org/10.1038/ajg.2009.86.CrossRefPubMed

43.

Chang JY, Talley NJ, Locke GR 3rd, Katzka DA, Schleck CD, Zinsmeister AR, et al. Population screening for barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc. 2011;86(12):1174–80. https://doi.org/10.4065/mcp.2011.0396.CrossRefPubMedPubMedCentral

44.

Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5(3):312–8. https://doi.org/10.1016/j.cgh.2006.12.008.CrossRefPubMed

45.

Ramirez FC, Akins R, Shaukat M. Screening of Barrett’s esophagus with string-capsule endoscopy: a prospective blinded study of 100 consecutive patients using histology as the criterion standard. Gastrointest Endosc. 2008;68(1):25–31. https://doi.org/10.1016/j.gie.2007.10.040.CrossRefPubMed

46.

Sami SS, Subramanian V, Ortiz-Fernández-Sordo’ J, Saeed A, Ragunath K. The utility of ultrathin endoscopy as a diagnostic tool for Barrett’s oesophagus (BO). Systematic review and meta-analysis United European Gastroenterology Week. Berlin; 2013.

47.

Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006;101(12):2693–703. https://doi.org/10.1111/j.1572-0241.2006.00890.x.CrossRefPubMed

48.

Sami SS, Subramanian V, Ortiz-Fernandez-Sordo J, Saeed A, Singh S, Guha IN, et al. Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. Gastrointest Endosc. 2015;82(5):782–92. https://doi.org/10.1016/j.gie.2015.07.016.CrossRefPubMed

49.

Moriarty JP, Shah ND, Rubenstein JH, Blevins CH, Johnson M, Katzka DA, et al. Costs associated with Barrett’s esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointest Endosc. 2017; https://doi.org/10.1016/j.gie.2017.04.019.

50.

Sami S, Pophali P, Halland M, DiPietro M, Enders F, Fernández-Sordo JO, et al. Feasibility and performance characteristics of a novel disposable transnasal capsule device for Barrett’s oesophagus screening: a prospective international multicentre trial. Gut. 2017;66(suppl 2):OC-003. https://doi.org/10.1016/j.gie.2017.03.101.

51.

Alashkar B, Faulx AL, Hepner A, Pulice R, Vemana S, Greer KB, et al. Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013; https://doi.org/10.1016/j.cgh.2013.10.014.

52.

Gora MJ, Sauk JS, Carruth RW, Gallagher KA, Suter MJ, Nishioka NS, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19(2):238–40. https://doi.org/10.1038/nm.3052.CrossRefPubMedPubMedCentral

53.

Sami SS, Ragunath K, Iyer PG. Screening for Barrett’s esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol. 2015;13(4):623–34. https://doi.org/10.1016/j.cgh.2014.03.036.CrossRefPubMed

54.

Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol. 2010;105(8):1729–37.CrossRefPubMed

55.

Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31. https://doi.org/10.1056/NEJM199903183401101.CrossRefPubMed

56.

Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123(2):461–7. https://doi.org/10.1053/gast.2002.34748.CrossRefPubMed

57.

Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, Hemminger LL, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101(1):12–7. https://doi.org/10.1111/j.1572-0241.2006.00379.x.CrossRefPubMed

58.

Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9. https://doi.org/10.1136/gut.2007.145177.CrossRefPubMed

59.

Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–7. https://doi.org/10.1136/gut.2004.051821.CrossRefPubMedPubMedCentral

60.

Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol. 2012;107(11):1655–61. https://doi.org/10.1038/ajg.2012.299.CrossRefPubMed

61.

Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33(4):306–9. https://doi.org/10.1097/00004836-200110000-00010.CrossRefPubMed

62.

Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106(2):254–60. https://doi.org/10.1038/ajg.2010.470.CrossRefPubMed

63.

Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol. 2005;3(1):1–10. https://doi.org/10.1016/S1542-3565(04)00602-0.CrossRefPubMed

64.

Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399–412.e7. https://doi.org/10.1016/j.cgh.2013.05.009.CrossRefPubMed

65.

Juhasz A, Mittal SK, Lee TH, Deng C, Chak A, Lynch HT. Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma. J Clin Gastroenterol. 2011;45(10):867–71. https://doi.org/10.1097/MCG.0b013e31821f44a8.CrossRefPubMedPubMedCentral

66.

Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet. 2012;44(10):1131–6. https://doi.org/10.1038/ng.2408.CrossRefPubMed

67.

Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang Y, et al. Germline mutations in msr1, ascc1, and cthrc1 in patients with barrett esophagus and esophageal adenocarcinoma. JAMA. 2011;306(4):410–9. https://doi.org/10.1001/jama.2011.1029.CrossRefPubMedPubMedCentral

68.

Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res. 2012;5(9):1115–23. https://doi.org/10.1158/1940-6207.CAPR-12-0010.CrossRef

69.

Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12(8):1267–71. https://doi.org/10.1016/j.cgh.2013.12.014.CrossRefPubMed

70.

Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108(3):353–62. https://doi.org/10.1038/ajg.2012.446.CrossRefPubMedPubMedCentral

71.

Crews NR, Johnson ML, Schleck CD, Enders FT, Wongkeesong LM, Wang KK, et al. Prevalence and predictors of gastroesophageal reflux complications in community subjects. Dig Dis Sci. 2016;61(11):3221–8. https://doi.org/10.1007/s10620-016-4266-3.CrossRefPubMedPubMedCentral

72.

Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58(5):661–70. https://doi.org/10.1016/S0016-5107(03)02011-X.CrossRefPubMed

73.

Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96(7):2005–12. https://doi.org/10.1111/j.1572-0241.2001.03933.x.CrossRefPubMed

74.

Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB. External validation of the Michigan Barrett’s esophagus prediction tool. Clin Gastroenterol Hepatol. 2017;15(7):1124–6. https://doi.org/10.1016/j.cgh.2017.03.004.CrossRefPubMed

75.

Atkinson M, Das A, Faulx A, Kinnard M, Falck-Ytter Y, Chak A. Ultrathin esophagoscopy in screening for Barrett’s esophagus at a veterans administration hospital: easy access does not lead to referrals. Am J Gastroenterol. 2008;103(1):92–7. https://doi.org/10.1111/j.1572-0241.2007.01501.x.CrossRefPubMed

Title: Recent Advances in Screening for Barrett’s Esophagus
Authors: Sarmed S. Sami, MRCP PhD
Prasad G. Iyer, MD MS
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 1/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-018-0166-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Recent Advances in Screening for Barrett’s Esophagus

Opinion statement

Purpose of review

Recent findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Opinion statement

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

Update on Bowel Preparation for Colonoscopy

POEM in the Treatment of Esophageal Disorders

Updates on Women’s Health Issues in Patients with Inflammatory Bowel Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page